ATNM
Actinium Pharmaceuticals, Inc. AMEX Listed Dec 27, 2012$1.23
Mkt Cap $38.6M
52w Low $0.95
28.0% of range
52w High $1.95
50d MA $1.16
200d MA $1.39
P/E (TTM)
-1.0x
EV/EBITDA
0.1x
P/B
4.5x
Debt/Equity
0.2x
ROE
-432.6%
P/FCF
-1.7x
RSI (14)
—
ATR (14)
—
Beta
-0.21
50d MA
$1.16
200d MA
$1.39
Avg Volume
176.2K
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
275 Madison Avenue · New York City, NY 10016 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.19 | -0.19 | -1.8% | 0.99 | +0.0% | +0.5% | -0.5% | -1.0% | +11.2% | +7.3% | — |
| Nov 14, 2025 | AMC | -0.25 | -0.16 | +36.0% | 1.27 | +8.7% | +14.2% | -1.4% | -4.9% | -5.1% | +3.1% | — |
| Aug 8, 2025 | AMC | -0.32 | -0.22 | +31.2% | 1.54 | +0.6% | -4.5% | +2.7% | +6.0% | +3.1% | +2.4% | — |
| May 9, 2025 | AMC | -0.26 | -0.51 | -96.2% | 1.48 | +1.4% | +4.7% | -1.9% | -3.9% | +4.8% | +9.2% | — |
| Mar 31, 2025 | AMC | -0.37 | -0.21 | +43.2% | 1.61 | -0.6% | -7.5% | +2.0% | -8.6% | -7.2% | -5.4% | — |
| Nov 14, 2024 | AMC | -0.35 | -0.37 | -5.7% | 1.65 | +0.6% | -9.1% | -5.3% | +0.0% | -2.1% | +5.8% | — |
| Aug 5, 2024 | AMC | -0.48 | -0.38 | +20.8% | 2.48 | -4.8% | +15.7% | -26.8% | +14.8% | -14.9% | -2.9% | — |
| Apr 26, 2024 | AMC | -0.42 | -0.31 | +26.2% | 6.87 | +0.4% | +7.4% | +4.3% | +1.0% | +12.5% | +2.4% | — |
| Mar 29, 2024 | AMC | -0.54 | -0.33 | +38.9% | — | — | — | — | — | — | — | — |
| Nov 2, 2023 | AMC | -0.53 | -0.49 | +7.5% | 4.58 | +2.6% | +3.9% | -4.4% | +7.7% | -1.2% | -3.5% | — |
| Aug 14, 2023 | AMC | -0.50 | -0.58 | -16.0% | 6.33 | -0.3% | +2.4% | -2.0% | -3.1% | +0.7% | -2.9% | — |
| May 15, 2023 | AMC | -0.42 | -0.43 | -2.4% | 8.94 | -3.1% | -5.9% | -0.2% | -0.2% | +3.7% | +3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Stephens & Co. | Maintains | Overweight → Overweight | — | $0.99 | $0.99 | +0.0% | +0.5% | -0.5% | -1.0% | +11.2% | +7.3% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.56 | +2.6% | +11.8% | -2.9% | -1.8% | -12.3% | -1.4% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.48 | $1.50 | +1.4% | +4.7% | -1.9% | -3.9% | +4.8% | +9.2% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.34 | +2.3% | -0.8% | +10.0% | +6.3% | -2.0% | +4.0% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.61 | $1.60 | -0.6% | -7.5% | +2.0% | -8.6% | -7.2% | -5.4% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.87 | $1.98 | +5.9% | +1.1% | -4.2% | -11.0% | -7.5% | +2.0% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.49 | $1.66 | +11.4% | +6.0% | +18.4% | +1.1% | -4.2% | -11.0% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.21 | $1.29 | +6.6% | +16.5% | +9.9% | -3.9% | +6.0% | +18.4% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.30 | $1.28 | -1.5% | -8.5% | +1.7% | +16.5% | +9.9% | -3.9% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.12 | $1.11 | -0.9% | +2.7% | +0.0% | +4.3% | +2.5% | +5.7% |
| Nov 19 | Stephens & Co. | Maintains | Overweight → Overweight | — | $1.42 | $1.41 | -0.7% | +0.0% | -2.1% | +5.8% | -1.4% | +0.0% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.66 | +0.6% | -9.1% | -5.3% | +0.0% | -2.1% | +5.8% |
| Aug 6 | Maxim Group | Maintains | Buy → Buy | — | $2.48 | $2.36 | -4.8% | +15.7% | -26.8% | +14.8% | -14.9% | -2.9% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.48 | $2.36 | -4.8% | +15.7% | -26.8% | +14.8% | -14.9% | -2.9% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.90 | $7.96 | +0.8% | -1.0% | -6.9% | -4.3% | -0.7% | -4.3% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.82 | $8.00 | +2.3% | +1.4% | -0.8% | -4.1% | -3.2% | +2.3% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.69 | $9.67 | -0.2% | -8.6% | -2.3% | -2.8% | +1.0% | -3.3% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.78 | $7.95 | +2.2% | +12.5% | +2.4% | -1.3% | -0.3% | -1.1% |
| Apr 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.38 | $7.31 | -0.9% | +4.3% | +1.0% | +12.5% | +2.4% | -1.3% |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.87 | $6.90 | +0.4% | +7.4% | +4.3% | +1.0% | +12.5% | +2.4% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.83 | $7.83 | +0.0% | +9.3% | +0.5% | +2.8% | +3.3% | +4.5% |
| Apr 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.83 | $7.83 | +0.0% | +9.3% | +0.5% | +2.8% | +3.3% | +4.5% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.67 | $8.77 | +1.2% | -6.3% | -2.2% | -1.4% | +9.3% | +0.5% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.54 | $7.60 | +16.2% | +25.5% | +4.8% | +5.9% | +1.0% | -5.8% |
| Mar 19 | Maxim Group | Maintains | Buy → Buy | — | $6.54 | $7.60 | +16.2% | +25.5% | +4.8% | +5.9% | +1.0% | -5.8% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.65 | $7.67 | +0.3% | -9.5% | -4.8% | +1.7% | -6.4% | +7.7% |
| Dec 11 | B. Riley Securities | Maintains | Buy → Buy | — | $5.32 | $5.68 | +6.8% | -7.5% | -6.1% | +11.9% | -1.5% | -4.7% |
| Oct 3 | B. Riley Securities | Maintains | Buy → Buy | — | $5.60 | $5.72 | +2.1% | +2.5% | +0.2% | +5.7% | -0.2% | -1.3% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.62 | $6.62 | +0.0% | -2.7% | +1.4% | +12.7% | -5.2% | -3.9% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.33 | $6.31 | -0.3% | +2.4% | -2.0% | -3.1% | +0.7% | -2.9% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.94 | $8.66 | -3.1% | -5.9% | -0.2% | -0.2% | +3.7% | +3.1% |
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.17 | $9.18 | +0.1% | -2.9% | +4.5% | +1.0% | -5.2% | -1.1% |
| Jun 4 | H.C. Wainwright | Maintains | Buy → Buy | — | $6.64 | $8.40 | +26.5% | +31.0% | +3.4% | +6.7% | +39.8% | +1.5% |
| Jul 12 | B. Riley FBR | Maintains | Buy → Buy | — | $20.09 | $20.25 | +0.8% | +9.0% | +7.2% | +1.1% | -3.4% | -0.6% |
| Dec 6 | B. Riley FBR | Maintains | Buy → Buy | — | $20.91 | $21.60 | +3.3% | -3.6% | +4.2% | +0.0% | -1.4% | -6.8% |
| Aug 25 | Roth Capital | Maintains | Buy → Buy | — | $49.80 | $50.40 | +1.2% | +2.4% | +1.2% | -1.2% | +6.5% | -0.6% |
| Feb 29 | H.C. Wainwright | Maintains | Buy → Buy | — | $59.40 | $61.50 | +3.5% | +1.5% | -1.0% | +3.0% | -2.4% | +1.0% |
| Oct 15 | FBR Capital | Maintains | Outperform → Outperform | — | $66.00 | $70.80 | +7.3% | +4.1% | -0.4% | +0.4% | +0.0% | -4.8% |
| Oct 1 | MLV & Co. | Maintains | Buy → Buy | — | $201.00 | $207.60 | +3.3% | -3.0% | -3.8% | -3.5% | +1.7% | -1.5% |
| Jul 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $208.20 | $213.00 | +2.3% | +5.3% | -1.5% | -2.2% | -0.7% | -0.9% |
No insider trades available.
8-K
Unknown — 8-K Filing
Artios Pharma will hold say-on-pay votes annually, indicating shareholder confidence in executive compensation structure and reducing governance risk for investors.
Mar 26
8-K · 5.02
!!! Very High
CNS Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
CNS Pharmaceuticals appointed a new executive with a $450,000 base salary, 40% bonus target, and 9,500 restricted stock units, signaling leadership continuity and commitment to retention.
Feb 17
8-K · 5.02
!!! Very High
Actinium Pharmaceuticals, Inc -- 8-K 5.02: Executive Change
Actinium Pharmaceuticals appointed Sandesh Seth as principal financial officer, signaling potential leadership restructuring that investors should monitor for strategic implications.
Feb 13
Data updated apr 24, 2026 7:38pm
· Source: massive.com